The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Table 3

The prognostic value of the IGFBP3 mRNA expression in ovarian cancer.

	Overall survival			Progression-free survival
	Cases	HR (95% CI)	value	Cases	HR (95% CI)	value
Histology
All cancer patients	1656	1.25 (1.08−1.44)	0.0031	1435	0.89 (0.77−1.03)	0.13
Serous cancer patients	1207	1.25 (1.05−1.48)	0.0099	1104	0.88 (0.75−1.05)	0.15
Endometrioid cancer patients	37	5.91 (0.66−52.98)	0.071	51	0.34 (0.12−0.95)	0.031
Pathological grades
I	56	0.59 (0.23−1.53)	0.28	37	2.67 (0.89−7.96)	0.068
II	324	1.36 (1.01−1.84)	0.045	256	0.81 (0.58−1.13)	0.22
III	1015	0.88 (0.74−1.03)	0.12	837	0.83 (0.68−1.01)	0.062
Clinical stages
I and II	135	1.56 (0.72−3.4)	0.26	163	0.59 (0.31−1.14)	0.12
III and IV	1220	1.2 (1.02−1.41)	0.028	1081	0.89 (0.75−1.05)	0.15
Chemotherapy
Contains platin	1409	1.21 (1.04−1.41)	0.014	1259	1.12 (0.99−1.28)	0.078
Contains taxol	793	1.15 (0.94−1.4)	0.17	715	0.82 (0.67−1)	0.049
Contains taxol+platin	776	1.13 (0.92−1.38)	0.24	698	0.8 (0.65−0.98)	0.029

.